
AstraZeneca Expands Portfolio with Strategic Acquisition of Cell Therapy Firm for Up to $1 Billion
15 hours ago
In a significant move to bolster its presence in the innovative field of biotechnology, AstraZeneca has announced its intention to acquire a leading cell therapy company, a strategic investment that could total up to $1 billion. This acquisition underscores the pharmaceutical giant's commitment to diversifying its offerings and enhancing its capabilities in the rapidly evolving area of cellular therapies.
Continue reading